Ubiquigent offers antibodies against full length or partial proteins, from the ubiquitin proteasome (UPS) pathway; these include E2 conjugating enzymes, E3 ligases, DUBs, ubiquitin binding proteins substrates and conjugate antibodies.
The anti-polyubiquitylated conjugates mAb (FK1) and the anti-mono and polyubiquitylated conjugates mAb (FK2) have been extensively characterised and can be used to demonstrate the specific recognition of polyubiquitylated and mono and polyubiquitylated protein conjugates respectively, but show no reactivity with free ubiquitin. Ubiquigent also offer a number of kinase antibodies, Like ubiquitylation, phosphorylation is a reversible post-translational modification. Abnormal protein phosphorylation is a cause or consequence of disease, including cancers, diabetes and inflammatory disease, while defects in genes that encode protein kinases and phosphatases underlie a number of inherited disorders. Around 500 protein kinases are encoded in the human genome and they account for around 25% of the molecular targets currently being pursued by drug discovery companies. It is becoming increasingly apparent that there is significant cross-talk between these two key intracellular systems; phosphorylation and ubiquitylation.
|ABIN1 (human; full length), pAb||68-0002-100||100 µg||£390||View|
|ABIN1 (mouse; full length), pAb||68-0001-100||100 µg||£390||View|
|AMPK alpha 2 (human; residues 352 - 366), pAb||68-0055-100||100 µg||£390||View|
|CAND1 (human; residues 5 - 245), pAb||68-0003-100||100 µg||£390||View|
|Cullin3 (human; residues 554 - 768), pAb||68-0004-100||100 µg||£390||View|
|Cullin5 (human; residues 577 - 689), pAb||68-0005-100||100 µg||£390||View|
|CYLD (human; full length), pAb||68-0006-100||100 µg||£390||View|
|DCNL3 (human; full length), pAb||68-0007-100||100 µg||£390||View|
|DCNL4 (human; full length), pAb||68-0008-100||100 µg||£390||View|
|DCNL5 (human; full length), pAb||68-0010-100||100 µg||£390||View|